PEP-CAG
MetabolicPeptide CAG
Overview
PEP-CAG is a designation used by certain research peptide vendors. Based on vendor naming conventions in which "PEP" denotes a proprietary peptide formulation and "CAG" likely indicates a cagrilintide-adjacent sequence (cagrilintide is a long-acting amylin analog developed by Novo Nordisk for obesity treatment), PEP-CAG may refer to a research-grade cagrilintide analog or a blend incorporating cagrilintide-related activity.
**No published peer-reviewed research exists for PEP-CAG as a named compound.** No molecular formula, sequence, or clinical data has been publicly disclosed by any vendor using this designation. The compound should be treated as a proprietary, unvalidated peptide with no independent scientific literature.
This entry is based on best-effort vendor name interpretation. The underlying biology of cagrilintide (amylin receptor agonism for appetite regulation and weight loss) is well-researched in the context of its parent compound, but nothing in that literature can be attributed to PEP-CAG specifically.
Mechanism of Action
If PEP-CAG is indeed a cagrilintide-related peptide, the presumed mechanism would involve amylin receptor agonism. Amylin (islet amyloid polypeptide, IAPP) is co-secreted with insulin from pancreatic beta cells and acts on amylin receptors in the hypothalamus and brainstem to suppress appetite, reduce gastric emptying, and decrease post-meal glucagon secretion. Cagrilintide is engineered as a long-acting amylin analog with once-weekly dosing, currently in Phase 3 development (CagriSema, NCT04982575) in combination with semaglutide.
Without confirmed sequence and pharmacological characterization of PEP-CAG, mechanistic attribution is speculative.
Research Dosing
PEP-CAG appears to be a vendor-specific designation used by research peptide suppliers. Based on naming conventions seen in vendor catalogs (where 'CAG' may denote a cagrilintide-related sequence), this likely refers to a proprietary analog or formulation variant rather than a named pharmaceutical compound. No clinical data exists.
Research data only. These dosing ranges are derived from published studies, primarily in animal models. This is not medical advice. No peptide discussed on this site is approved for human therapeutic use unless otherwise noted.